Neovasc (NASDAQ:NVCN – Get Rating) (TSE:NVC) is set to post its quarterly earnings results after the market closes on Thursday, August 11th. Analysts expect Neovasc to post earnings of ($1.25) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.
Neovasc (NASDAQ:NVCN – Get Rating) (TSE:NVC) last posted its quarterly earnings data on Thursday, May 12th. The medical equipment provider reported ($3.01) EPS for the quarter, missing analysts’ consensus estimates of ($1.25) by ($1.76). Neovasc had a negative return on equity of 50.69% and a negative net margin of 1,192.20%. The firm had revenue of $0.61 million during the quarter, compared to the consensus estimate of $0.80 million.
Neovasc Stock Up 3.4 %
NVCN opened at $7.86 on Thursday. Neovasc has a one year low of $4.59 and a one year high of $21.56. The company has a debt-to-equity ratio of 0.27, a quick ratio of 12.50 and a current ratio of 12.88. The stock’s fifty day moving average is $6.03 and its 200-day moving average is $9.47. The company has a market capitalization of $21.26 million, a PE ratio of -0.65 and a beta of 2.30.
Analysts Set New Price Targets
Neovasc Company Profile
Neovasc Inc, a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina.
- Get a free copy of the StockNews.com research report on Neovasc (NVCN)
- Is it Time to Tap Molson Coors or Will Beer Sales Turn Flat?
- There Are Different Types of Stock To Invest In
- PayPal Continues To Struggle As Competition Increases
- Two High-Yield Deep-Values You Shouldn’t Ignore
- Is Starbucks Shooting For The Moon?
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Neovasc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc and related companies with MarketBeat.com's FREE daily email newsletter.